TRexBio IPO: $14 pricing on 2026-10-08
TRexBio priced 8,333,334 shares at $14 in its dated 2026-10-08 announcement, with approximately $116.7 million base gross proceeds.
Dated offering terms — 2026-10-08
TRexBio announced a price of $14 for 8,333,334 shares, representing about $116.7 million before fees. Its announcement expected Nasdaq Global Select Market trading under TRXB on 9 October 2026. Closing was expected on 13 October 2026, subject to conditions.
The company works on medicines based on tissue regulatory T-cell biology. Its announcement gives underwriters an option for 1,250,000 extra shares. A separate 13 October issuer announcement confirms that the IPO closed.
What the financing changes
The investment question is how financing translates into evidence that immune regulation produces useful clinical outcomes. A biological mechanism and successful fundraising answer different questions. Follow-up trial disclosures should explain dose selection, durability and patient outcomes. Investors can then compare the resulting development plan with cash consumption. The additional-share option should also be tracked separately from the original base deal, because exercising it changes both proceeds and the share count.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.